KRAS and granular cell tumor: Clinically significant mutations (<i>KIT</i>: Asp816Val, Ala829Pro; and <i>KRAS</i>: Gln61Leu) suggest potential therapeutic targets for GCT, while <i>MTOR</i>, <i>PIK3CA</i>, and <i>AKT2</i> emerge as candidates for targeted therapy.<h4>Discussion</h4>These findings provide insights into the genomic alterations of pediatric GCTs and emphasize the potential for targeted therapies.